1st Quarter - Report — SAM ACTION, INC. for SAM ACTION, INC. (2019)

Firm

SAM ACTION, INC.

Client

SAM ACTION, INC.

Income

—

Expenses

$10,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

draft legislation of the MEDS Act to lower the barriers of researching marijuana

Lobbyist	Covered position, as disclosed
GARTH VAN METER	Deputy Chief of Staff, Rep. John Fleming (LA-4)

Contacted: Food & Drug Administration (FDA); White House Office; SENATE; Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); Justice, Dept of (DOJ); Natl Institutes of Health (NIH)

Law Enforcement/Crime/Criminal Justice LAW

draft legislation of the STATES Act to legalize marijuana, appropriations amendments related to marijuana legalization

Lobbyist	Covered position, as disclosed
GARTH VAN METER	Deputy Chief of Staff, Rep. John Fleming (LA-4)

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Justice, Dept of (DOJ); Drug Enforcement Administration (DEA); Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE

Banking BAN

H.R. 1595 SAFE Banking Act on marijuana banking and investment

Lobbyist	Covered position, as disclosed
GARTH VAN METER	Deputy Chief of Staff, US Rep. John Fleming (LA-4)

Contacted: Drug Enforcement Administration (DEA); Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); SENATE; Food & Drug Administration (FDA); Justice, Dept of (DOJ); White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1595 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.